Hr Her2 Breast Cancer clinical trials

Explore recruiting hr her2 breast cancer clinical trials.

Recruiting hr her2 breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hr Her2 Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer

France

Therapeutic use (Phase IV) EU CTIS Study details

LESS : Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

France, Denmark, Sweden, Belgium, Poland, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Italy, Czechia, Germany, France, Spain, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)

Poland, Spain, France, Italy, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hr Her2 Breast Cancer trials by city

Hr Her2 Breast Cancer in Toronto Hr Her2 Breast Cancer in Vancouver Hr Her2 Breast Cancer in Montreal Hr Her2 Breast Cancer in Calgary Hr Her2 Breast Cancer in Edmonton Hr Her2 Breast Cancer in Ottawa Hr Her2 Breast Cancer in Winnipeg Hr Her2 Breast Cancer in Quebec City Hr Her2 Breast Cancer in Hamilton Hr Her2 Breast Cancer in Kitchener Hr Her2 Breast Cancer in London Hr Her2 Breast Cancer in Halifax Hr Her2 Breast Cancer in New York Hr Her2 Breast Cancer in Los Angeles Hr Her2 Breast Cancer in Chicago Hr Her2 Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease